Neurol eptic medi cation has been wid ely used in th e treatment of schizo phre nia since th e 1950 's. O ve r th e past d ecad e, howeve r, we have see n sig nifica n t advan ces in o ur unde rstandi ng of th ese m edi cation s ( 1,2). O nly re cent ly, for inst an ce, has t he effect of do se on efficacy a nd side effects been e lucida te d . Th is has led to more refined dosing strat egi es, with a n incr eased appreciati on for th e toxi c effec ts of t hese m edi cations. Lon g acting d ecanoat e pr ep aration s have a lso beco m e be tt e r und ers too d, a nd have e n te re d widespread clinica l usc. Ind eed , d eca noa te pr eparati on s can now be see n as th e pr eferred medi cation for m an y ch ro nica lly ill pat ie nts. Fin all y, a g rea t deal of exc ite me nt ha s been ge ne ra ted by t he d evelop m en t of novel medi cati on s with incr eas ed efficacy a nd d ecr eas ed side effec ts. C loza pin e a nd risp eridon e hav e becom e wid e ly ava ilable, and expe rime n ta l m edi cation s suc h as ola nzapin e are show ing g rea t promise . The availa bility of new medi cati on s has co m bine d with a n improved und erst anding of psych opharmacology to make o ptima l me d icat ion ma nage me nt more co m plex . This pr esents a un iqu e opport un ity for psychiat ris ts to tak e a lead e rship rol e in co m m unity ment al health treatm ent o rg a niza t ions as a skilled psychopharmacologi st.
DO SING ST RATE GIES
Only recently have re sea rc he rs begun to e luc ida te th e effec t of neu rol e ptic dose on response and toxi ci ty (3, 4) . Pr eviously th ere was a gen eral beli ef th at more was *Researc h Fell ow, Rob ert Wood J ohnson C linica l Scho la rs Pro g ra m , De pa rt m e n ts of Med icine a nd Psychi at ry, UC LA a nd W est Los An gel es Ve te ra ns Affa irs Medi cal C ent er, Los An geles, Ca lifo rn ia.
III bett er, and that littl e harm cou ld co me from high d oses. Ind e ed , clinic a l strategies, su ch as " ra pid neurol eptization" advocat ed the use of high-dose treatm ent of acu t e psychosis. Thes e approach es did not withstand ca re fu l study (5) . Indeed , research e rs have recently found a dose-r esponse cu rve for co nve n t iona l neurolept ics in which mod erat e doses produce m aximal improvem ent (6) . The optimal d ose for a cu te psychosis appears to be in th e rang e of 10-1 5 mg per day of hal op erid ol (4,7) , and some studi es sugges t that pati ents improve on substantiall y lower do ses (8) . W hile there has be en less res earch on th e dose-response cha rac te r istics of o ther conve ntional neurol eptics, a similar rel ationship has be en s ugges te d for fluph e na zin e , trifluoperazin e and thiothix en e (9) . Whil e typi cal d osa ge levels va ry bet we en differe n t neuroleptics, conve rs ion fa ctors allow doses of eac h neurol epti c to be un d e rstood as an approximat e haloperidol eq u iva le n t dose ( 10) .
Of cou rse , th ere is th e rare patient who ac t ua lly ben efits fro m more t han 10 or 15 m g per day of haloperidol. Why, therefore, take a cha nce by tapering a pati en t 's dose? There are several very convincing reasons for tapering doses, with th e goal of esta blis hing th e minimum e ffec t ive dose for eve ry patient. First , it is likely th a t many pati ents on very hi gh dos es of neurol eptic a re, in fac t, minim all y res po nsiv e or nonresponsive to neuroleptics. Betwe en 10 and 40% of peopl e with sc h izo p hrenia a re nonrespon sive to traditional neurol eptics (II). These pati ent s ofte n get t he ir dos es st eadily in cr eas ed in an att empt to co n t ro l persist ent sym p to ms, resulting eventually in sedation and che m ica l restraint. Oft en these pati ents ca n be m ana ged q uite we ll with low dose neurol eptic combin ed with behavioral therapi es suc h as social ski lls training (12) or a pot ent benzodiazepine su ch a s clonazep am ( 13) .
Th e ri sk of tardive dyskinesia is well known , a nd is th ou ght to occur in a p pr ox ima te ly 4% of pati ents for eve ry year of neurol eptic exposure ( 14) . Whil e tardive dyskinesia has not been proven to be d ose-relat ed , th ere a re strong t heoretica l and ex pe r ime n tal r easons to beli eve th at d os e m ay play a n import ant ro le ( 15) . Th ere has als o be en a n in cr eased recognition of th e ac u te side effects of oral neurol eptics. Acut e ex t ra pyr a m id a l side effec ts, su ch as dyst on ias , are we ll-known a nd do se-relat ed. Akathisia is do se-relat ed , ca n be difficult to trea t , a nd m ay lead to behavioral disturbances and treatm ent non compli ance (4) . Othe r com m on sid e e ffec ts, including apathy, a n he do nia, and a kinesia, a re sim ila r to th e nega tive sym p toms of schizophrenia , and th e refore ea sy to ove rloo k. Whil e so me of th ese sid e e ffec ts ca n be a me lio ra te d with m edication, oth ers, suc h as sex ua l d ysfunct ion , are ge ne r a lly resi st ant to a ny t hing other th an a cha nge of d ose or m edi ca ti on . Fina lly, th ere is r ecent evide nce that vocation al a nd soc ia l fun cti onin g worsen s on higher doses of neuroleptics (16, 17) .
Sin ce neurol eptics ca n have a dve rse e ffec ts a t eve n m od e rat e d oses, clinicians ne ed to titrat e ca re fully dose and effec t ( 18) . Even if a m od erat e dosa ge is effect ive in producing a rem ission of positive sym p to ms, a lower do se m ay be adequat e for av erting a m ajor r elaps e. However, int ermitt ent dosing or " d r ug holid ays" have be en shown to significantly in crease th e cha nce of r elapse , a nd a re not ge nerally r ecomm end ed (2) . On e should assum e th at , a t a ny g ive n tim e , th ere is a n op t imal dose for eac h patient whi ch ca n be found by wei ghing ben eficial a nd a dverse effects. It is not uncommon for t his optimal do se to be below th at need ed to remove all psych oti c sym p to ms. Maximal functioning m ay ofte n be ac h ieved even wh en th e pa ti en t co n t in ues to hav e so me psych otic sym p toms . Th e refo re , it is cr uc ia l that pati en ts be ta ugh t to recogn ize sym p to ms a nd side effects, a nd to communicat e th ese to th e ir p hys icia n. Whil e this so rt of ed uca t io n can be ti m e co nsuming, it has been s hown to red uce re la pse ( 19) . Pat ient s can be ta ught to ra t e eac h important sympt om a nd side-e ffec t o n a d ail y basis. When th e ph ysician uses t h is in fo r m a t io n and compl e t es a Bri ef Psychiatric Rating Scal e (20) a t each visit , th e " minimal effe c tive do se " ca n be re adily d et ermin ed . Thi s d ose , whe n fa it hfu lly used , a llows th e pat ient to ni aximi ze fun ctioning and qu al it y of life .
There is good rea so n to beli eve th at th e effectiv e us e of neurol eptic m edica tio n r equi res an in tegration of psy cho p harmaco logy and psy ch osocial reh abili tation (2 1). Fo r inst ance, psychi atri st s ne ed to kn ow how a patie n t is fun ctioning in o rde r to ar rive a t a n optim al m edicat ion regim en. Also, pa tie n ts need to have access to int ensiv e psych oeducation a l progra m s th at t each the m a bout th e symptoms of th eir m ental illness and the side effec ts of th eir m edica tio n. This ed uca tion m ay, in m an y organiza tions, be mos t cost-effect ively perform ed by a non-psychiatrist. These co lla borative approac hes req uire, howeve r , t hat t he psychiatrist is availabl e to s u pe rvise ot he r cl in icians a bout m ed ication and com m u n ica te with th em regarding th e curre n t sta t us of re habilitat io n effo r ts . T h is co lla boration is not likel y to occur if th e psychi at ri st is not a n int egra l me m be r of th e treatm en t team . Community m ent al hea lth organ iza t io ns th at limit psy chi atri st s to sig n ing prescr ip ti ons are unlik ely to provide t he fu ll ben e fit s of m od ern psyc ho p harmacology to t heir patients.
DEPOT PREPARATI O NS
Inj ect abl e d ep ot neu roleptics s ho uld be conside r ed in a ll people with ch ro n ic psych otic illn ess, a nd s hou ld g u ide th e initi al cho ice o f o ra l m ed ica t io n. Use of inj ect able m edication is not limit ed to the typical " no n-co m plia n t " pati ent. Even co m plia n t pa ti ent s have exace rba t ions, a nd t he paranoia a nd di sorgani zati on th at accompan ies th ese o ften lead to d iscont inuat io n of medicat ion. This m ay incr ea se th e len gth and severi ty o f th e re lapse . Inj ecta bl e m ed ications also a llow more pr ecise ti t ration o f d ose a nd respon se , since t he de livery of medication to th e brain is more re lia ble th an wit h o ral m edication and in t ermitt ent " m issing" of a do se is les s o f an issu e . Fin all y, intramu scula r m edi cat ion can result in less severe ex t ra pyr a m id a l side effects than ora l preparation s. Pati ent s sho uld be told th a t injectable m edi cation will lower t he ir ri sk of r elapse a nd can red uce their total long-t e r m neuroleptic ex pos ure.
Whe n arriving at a m illigram dos e fo r d epot m edication, it is reasonabl e to begi n wit h a I : I oral-to-decanoate co nve rsio n for fluphenazine d ecanoat e given eve ry two o r th re e we e ks. Si m ila r ly, it is reaso na ble to begin with a I: I0 oral-to-d ecanoat e conve rsio n for hal op eridol d ecanoa te g iven mon t h ly (22) . For example, a pati ent wh o is taking 5 m g ha lop eridol d ail y wo uld be ex pect ed to req u ire ro ugh ly 50 m g of hal operidol d ecanoat e pe r m onth. W h ile th ere is variation be twe e n pati ent s a nd d isagreem ent a bo u t op t imal conve rsio n fac tors, th es e ratios provid e go od star t ing points. Aft er beginning d ecanoat e prep aration s, o ne must be s ure to con t in ue o ra l m edica ti on s for a t lea st o ne to two m onths, sinc e it ca n tak e 3 to 5 doses of d ccanoat c before a ste a dy sta te is reach ed (23 ) . Whil e t echniqu es have been d eveloped for " loa d ing" pat ients with d ecanoat e wi thout co nc o m itan t use of oral m edi ca t ion, g rad ua l transition fr om oral to d ecanoat e m edi cation produces th e most consiste n t pla sm a co nce n t ra t io ns (24) .
Th e lon g half-li fe o f deca noa te a lso di ct at es that upwa
ca n le ak sig nifica n t ly a t th e inject ion site . Pract iti oners should, therefore , use a " Z-t r ac king" techniqu e to ens u re cons is te n t m edicat ion d el ive ry (25) . Z-Tracking involves manu all y m ovin g su perficia l t iss ue a nd m uscl e before d ecanoat e inj ection so th at the ne edl e t rack does not re main co n t ig uous with th e inj ecti on site. Us ing a small ga uge need le m ay a lso hel p re d uce leak a ge .
NOV EL MEDI CATIONS S t ud ies sho w th at ro ug hly one -t h ird of people with sc hizoph renia show litt le imp rov em ent with tradition al neu rol eptic me dica t ions ( I I). Th ese pat ient s hav e been t erm ed " ne urole p t ic nonresp onders" (26)
. While st ra tegies su ch as cha ng ing to a different neurol ept ic, using a hi gh do se, or a ug me n t ing with lithium occasio na lly help non-responsive pati ent s, th ey ge ne rally p rov e in effecti ve (27) . Th ese nonresponsive pati ent s hav e, however, been dram aticall y helped by th e d evelop m e n t of novel a nt ipsyc ho t ic m edi cati on s . This di scu ssion will focus m a inl y on c1ozapine, sin ce this is th e only m edi cati on that ha s been clearly sho wn to be more e ffect ive t han oth er a n t ipsyc ho t ic m edicat ion s. An oth er recently ava ila ble a n tipsyc ho t ic me dic a tion is risperidone , a n a gent with sig nifica n t a n tagonis t ic ac t ivity a t d op a min e, seroton in , a nd alpha -adren ergic r ecept ors. It ha s been sho wn to have a uniqu e sid e-effe ct p ro file , with a reduced liability for ex t ra py ram idal sym p toms a t e fficac io us doses (28) . Th e o ne la r ge st udy exam ining thi s m edi cati on found th at r isp eridon e als o improved negative sym p to ms, however, furth er rese arch will be ne ed ed to d e t e r mi ne wh et her thi s is secondary to a low er level of parkinsoni an side-effec ts. In a ny case , as a result of ri sp eridon e's sign ifica n t a n t i-sero to ne rgic ac t ivity, it has a u n iqu e sid e-effect profil e a nd ha s p roven to be well tolerat ed . It ha s, on this basis, e n te re d wid espread use as a n important clin ica l tool.
C loza pine, while m ore diffi cult to usc t han ot he r a n ti psyc ho t ic med ications, is clini call y fairly we ll und erstood . An y co m m u n ity m ent al health organization tha t treat s m ore th an a few peopl e with sc hizo p h re nia sho uld be usin g c1ozap ine. While m uc h press ha s been m ade a bo u t clozapine 's e fficacy wit h t he " nega t ive " o r d efici t sym p to ms of sc hizoph renia , in fact a ll ne u role ptic m ed ica tio ns t reat negative sym ptoms to so me d egr ee (29) . C loza pi nc's use fuln ess a p pears to a ris e from th e fa ct tha t J EFFERSO N J O URNAL OF PSYCHI ATRY it t reats both negative and posruve sy m p to ms m ore effec tiv e ly tha n an y o t he r available antipsychotic m edication (30, 31) . Whil e t he e fficacy o f ri sp eridone ha s not ye t be en adequat ely co m pare d to c1ozapine , preliminary clinical ex pe r ie nce suggests that it may not be a s effec t ive in se ve re ly ill pati ent s. Cl ozapine is a lso useful because it is th e only cu r re n t ly availabl e antipsychotic m edication th at ca uses ve ry few or no parkinsonian side effec ts . Finall y, ex te ns ive ex pe r ie nce with cloza pine indica tes th a t it ca uses very littl e o r no t ardive dysk in esia . In fa ct , tardive dyskin esia oft en improves with cloza pine treatm ent (32) , m aking this th e m edication of cho ice fo r people with psych ot ic illnes s and se ve re or progres siv e tardive m ovem ent d isord ers.
Given th e risk o f agra n u locy to sis, c1ozapin e 's use s ho u ld us uall y be lim it ed to th e following clinical situations: I) inad equat e r esponse to co nve n tional a n tipsychotic m edications, 2) di sabling o r progres siv e tardive dyskin esia , o r 3) unm ana gea ble side e ffects on other a n t ipsyc ho tic m edi cati on s (33) . Inad equ at e res po ns e to co nve n tio na l agents is oft en int erpret ed as m eaning that significant positive sympto ms have persist ed d espit e ade q ua te tri al s of tw o different neurol eptic m edi ca ti ons. T he re is no reason to su sp ect that cloza pine should be limit ed to pati en ts with a ny part icu la r psy chotic diagnoses. Clozapine has be en shown to be effec t ive in both sch izop h ren ia and sc h izoa ffec t ive di sorder, a nd has been success fu lly used in re fr acto ry bipola r di sord er and borderline personality di sord er with psych osis (34, 35) . The o nly a bsolu te co n t r a ind ica t io ns to cloza pine are a hemat olo gic di sorder pr edi sp osi ng to g ra nu locytopenia , previ ous leukop enia with c1oz apin e , a nd co ma tos e stat es.
C lozapine ca n ca use a number of side effec ts (36) . Co m mon mi nor side e ffects includ e sedation, excessive drooling and weight ga in . Sedati on oft en occu rs with d osa ge in cr ea ses , ge ne ra lly r esolves with tim e , and ca n be mini mi zed by giving th e e n t ire d ail y d ose of cloza pine a t bedtim e. Droolin g ca n be m an aged by placing a towe l on th e pillow at night, or, if nec essary, by using a n a n t icho line rg ic m edi cat io n. W ei ght ga in is managed with di et a ry m odifi cation a nd ex e rcis e. Less fr equ en t sid e e ffec ts includ e tach ycardi a , in creased body temperature a nd ort hos tat ic hypo t ension . Tachycardia and t emperature increas es a re usu all y mild and ofte n d o not require int ervention. They must , however, be differentiat ed fro m th e m ore seriou s (a nd ra re ) N eurol epti c M ali gnant Syndrome. Orthostatic hyp ot en sion can oft en be managed by having th e patient cha n ge position slowly, a nd increase fluid a nd salt int ak e . Overall, c1oza pine 's minor sid e-e ffec ts a re usually easy to m anag e. \"'ith th e exc e pt io n of weight g ain , th ey ge ne rally r esolve with tim e a nd a re less seve re if t he m edi cat ion do se is titrat ed up slowl y. If a tte nde d to a pp rop ria te ly, th ey s ho u ld rarely lead to m edication di scontinu ation . In fact , m ost pati ent s find c1ozapine 's sid e-effects to be preferable to those a ssociat ed with trad itional neuroleptics.
Serious side e ffec ts of cloza pine includ e respirat ory a r res t, se izu re , and ag ranulocyt osis. Respirat ory a r res t is quit e rare, a nd see ms mo re lik ely wit h t he first dose a nd wh en th e patient is taking a respiratory d epressant. For this reason, pa tient s sho uld not be on benzodi a zepin es wh en sta r t ing c1ozapin e. Also, a ll pa tie nt s mu st star t a t a d ail y dose of 12.5 m g , a nd must rest art a t this dose aft er be in g off cloza pine for more th an on e d ay. Seizures occur in 2-3% of pati ent s a t low d oses (less th an 450 m g) , in 5-6% of patients a t high er doses ( mo re th an 650 m g ) , a nd appear to be re la ted to t he ra te of dosage increase . C lozapin e may not be us ed a t do ses a bove 900 m g per day. If a seizure occurs, the cloza pine dos e should be cu t in hal f and t he pati ent se n t for neurologi c eva lua t io n. If this neurolo gic eva lua t ion is normal, valproat e ca n be begun a nd th e cloza pine dose slowly in crea sed as needed. As with se iz u re s ca used by traditional neurol epti cs, the se izu res with clozapine are often readi ly co n t rolle d .
Agra nu locytosis occurs in a bout 1% of pati ents (37) , and d eath du e to agran ulocytosis h as occurred in about 0.05 % of pati ents. Deaths du e to agranulocyt osis may, how eve r, be more than offs et by r eductions in mort a lit y du e to improved t reat m e nt of sch izophreni a (38 ) . Because a ll pati ents in th e U n ite d St at es must have t hei r whit e blood ce ll co u n t test ed we ekl y before receiving th eir m edication , agra nu locytosis is readily d et ect ed a nd treat ed. Be twee n Febru ary 1990 a nd M ay 1992 140 cases of a granulocytosis occurred, and th ere were 7 d eaths r elat ed to agran u locy tos is. All of th es e deat hs occurred in pat ients who were a t o r above 40 years old (39) . Th e first d eath was wide ly report ed, a nd occurred in a pati ent wh o wa s a lso tak in g carbamazepin e (40) . C arbamazepine , a nd o t he r m edication s th a t ca use le ukopenia, sho uld be used with ca u t ion in patients o n c1oz apine .
Over th e year e nd in g April 1992 , tw enty-three th ou sand pati ents we re enrolled in cloza pine treatm ent sys te m s. Thes e syst ems include a psychi at ri st , a ph a r m acist and a la bor a tory, and req uire a great d eal of paperwork a nd a d m in is t ra ti ve effort. For t h is reaso n, pharmacists have cre a te d co ns u lt ing groups whi ch co m ple te th e paperwork a nd other ad m in ist r a t ive work asso ciat ed with c1oza pine . Our cli nicians hav e had s uccess workin g with a loca l co ns ult ing bu sin ess th at cha rges t he pa tient a bo u t 20 per week for th eir servi ces (4 1). They h av e m ad e clozapine as easy to us e a s a ny o t he r neuroleptic m edication, and have facilit at ed o u r use o f clozapine at a loca l public m ental health clin ic.
There have been a number of prom in en t obst acl es to th e use of cloza pinc in public m ent a l heal t h systems (42) . Most of th e peopl e who wou ld ben efit from cloza pine have se ve re ch ro n ic sc h izop h re nia, and mo st of th ese peopl e are t reat ed in these public sys te m s. U n fo rt u na te ly, th e av a ila bility o f cloza pine in th e public se ctor ha s been gu ide d m ore by ad m in ist rat ive than clinical forces. These pu blic systems have been accusto me d to ca ring for th e se rious ly ill while s pe nd ing r em arkably littl e mon ey on psychiatric treatm ent. Pati ent s are oft en seen eve ry one to th ree m onths by psychiat rists who are a llowed on ly a few m inut es per pati en t to pr escribe m edi cat ion . Minim izing t he ro le of psychiatrists has m ad e the introduction of clozapine tragicall y slow in m any publ ic m ental health clinics.
Public sys te ms' r elu ctance to ado p t new clinical t echnologi es s uc h as clozapine ca n be ove rcome by pressure from psychiatrist s a nd co ns u mer organizat ions. The National Alli ance for th e M entally III wa s instrum ental in th e d ecision by th e federal gov ernm ent to force sta te M edi caid programs to pay for c1ozapin e . U nfo rt u na tely, many stat e and local gov er nm ents have not implem ent ed th e clinica l reforms necessary to actually make cloza pine ava ila ble in public clinics. Th e use of clozapi ne in th es e clinics r equires ed uc a t io n of clinic sta ff, a n increase in clin ica l a nd adrn inis-J EFFERSO N J O URN AL OF PSYCH IATRY trat ive r esources fo r se r io us ly ill pat ients, a nd su pervisio n of a mul ti-discipli na ry team by a psychiatrist wh o will prescribe clozapin e.
C ONC LU SIO N
Over th e pa st d ecade , we h av e wi tnessed signifi cant progress in th e psyc hopharm a cologi c m ana gem ent of psych otic di so rd ers. Min im al e ffec t ive d osing , d epo t m edication, a nd novel a gents ha ve sig n ifica n t ly improved the res ponse o f sc h izo p h ren ia to treatment. Th es e n ew cl in ical t echnologi es hav e not , how ev er, bee n ado p te d by many o f th e public o rga n iza t io ns that ca re for these p ati ent s. Thi s lack o f availa bi lity o f s ta te-of-t he-a rt treatm ent h a s ra ised sig n ifica n t qu es ti o ns a bo u t th e qu alit y of care d eli ve r ed in publ ic sys te ms (+3) . Improving this qu ality will begin wi th psychiat ris ts a nd co ns u me r ad voca t es who in sist o n th e a va ila b ility of these n ew clinica l te c hruq u es ,
